title: Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer.
abstract: BACKGROUND
  To analyze the rate of larynx preservation in patients of locally advanced hypopharyngeal cancer treated with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy, and compare the results with patients treated with primary surgery.
  
  
  METHODS
  Between January 2003 and November 2007, 14 patients were treated with primary surgery and 33 patients were treated with concurrent chemoradiotherapy (CCRT) using IMRT technique. Survival rate, larynx preservation rate were calculated with the Kaplan-Meier method. Multivariate analysis was conducted for significant prognostic factors with Cox-regression method.
  
  
  RESULTS
  The median follow-up was 19.4 months for all patients, and 25.8 months for those alive. The 5-year overall survival rate was 33% and 44% for primary surgery and definitive CCRT, respectively (p = 0.788). The 5-year functional larynx-preservation survival after IMRT was 40%. Acute toxicities were common, but usually tolerable. The rates of treatment-related mucositis (> or = grade 2) and pharyngitis (> or = grade 3) were higher in the CCRT group. For multivariate analysis, treatment response and cricoid cartilage invasion strongly correlated with survival.
  
  
  CONCLUSIONS
  IMRT plus concurrent chemotherapy may preserve the larynx without compromising survival. Further studies on new effective therapeutic agents are essential.
authors.affiliation: Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
authors.forename: Wen-Yen
authors.initials: WY
authors.lastname: Huang
authors.forename: Yee-Min
authors.initials: YM
authors.lastname: Jen
authors.forename: Chang-Ming
authors.initials: CM
authors.lastname: Chen
authors.forename: Yu-Fu
authors.initials: YF
authors.lastname: Su
authors.forename: Chun-Shu
authors.initials: CS
authors.lastname: Lin
authors.forename: Yaoh-Shiang
authors.initials: YS
authors.lastname: Lin
authors.forename: Ying-Nan
authors.initials: YN
authors.lastname: Chang
authors.forename: Hsing-Lung
authors.initials: HL
authors.lastname: Chao
authors.forename: Kuen-Tze
authors.initials: KT
authors.lastname: Lin
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Chang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D050397:Radiotherapy, Intensity-Modulated; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin; D005472:Fluorouracil
references.citation: Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68
references.pmid: 17493769
references.citation: Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):966-74
references.pmid: 17145527
references.citation: Gynecol Oncol. 2004 Mar;92(3):744-51
references.pmid: 14984936
references.citation: Clin Otolaryngol Allied Sci. 2001 Feb;26(1):59-61
references.pmid: 11298170
references.citation: J Clin Oncol. 1996 Mar;14(3):838-47
references.pmid: 8622032
references.citation: Oncologist. 2007 May;12(5):555-64
references.pmid: 17522243
references.citation: Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):424-32
references.pmid: 18755554
references.citation: N Engl J Med. 2004 May 6;350(19):1937-44
references.pmid: 15128893
references.citation: J Clin Oncol. 2003 Jan 1;21(1):92-8
references.pmid: 12506176
references.citation: World J Surg. 2003 Jul;27(7):832-7
references.pmid: 14509515
references.citation: J Natl Cancer Inst. 1998 Jun 3;90(11):824-32
references.pmid: 9625170
references.citation: Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1419-26
references.pmid: 16154712
references.citation: Head Neck. 1996 Sep-Oct;18(5):405-11
references.pmid: 8864731
references.citation: Int J Cancer. 2000 Apr 20;90(2):92-103
references.pmid: 10814959
references.citation: Cancer. 2000 Feb 15;88(4):876-83
references.pmid: 10679658
references.citation: Strahlenther Onkol. 2006 Jun;182(6):331-5
references.pmid: 16703288
references.citation: Lancet Oncol. 2008 Apr;9(4):367-75
references.pmid: 18374290
references.citation: J Clin Oncol. 1993 Oct;11(10):1873-8
references.pmid: 8410112
references.citation: Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73
references.pmid: 15925451
references.citation: Clin Otolaryngol Allied Sci. 1991 Oct;16(5):466-9
references.pmid: 1742894
references.citation: Head Neck. 2001 Sep;23(9):713-7
references.pmid: 11505479
references.citation: J Natl Cancer Inst. 1996 Jul 3;88(13):890-9
references.pmid: 8656441
references.citation: Acta Oncol. 2009;48(3):431-9
references.pmid: 18781445
references.citation: N Engl J Med. 2006 Feb 9;354(6):567-78
references.pmid: 16467544
references.citation: Radiother Oncol. 2009 Jul;92(1):4-14
references.pmid: 19446902
references.citation: J Clin Oncol. 2006 Jun 10;24(17):2618-23
references.pmid: 16763274
references.citation: Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22
references.pmid: 12007936